Optimal treatment with telaprevir for chronic HCV infection

Authors

  • Arun B. Jesudian,

    1. Division of Gastroenterology and Hepatology, Center for Study of Hepatitis C, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA
    Search for more papers by this author
  • Ira M. Jacobson

    Corresponding author
    • Division of Gastroenterology and Hepatology, Center for Study of Hepatitis C, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA
    Search for more papers by this author

  • When citing this article, please use: Jesudian, A.B. and Jacobson, I.M. Telaprevir for Chronic Hepatitis C Virus Infection. Clinics in Liver Disease 2013; 17:47–62

Correspondence

Ira M. Jacobson, 1305 York Avenue 4th Floor, New York, NY 10021

Tel: (646) 962-4040

Fax: (646) 962-0433

e-mail: imj2001@mail.med.cornell.edu

Abstract

Telaprevir is a recently approved direct-acting antiviral against hepatitis C virus (HCV) that works through inhibition of the NS3/4A serine protease inhibitor.Phase 2b and 3 studies have shown marked increase in sustained virological response rates in both treatment- naïve and treatment-experienced patients with HCV genotype 1 treated with a telaprevir-containing regimen compared with pegylated interferon (PEG-IFN) and ribavirin alone. The most commonly observed side effects of telaprevir therapy are anaemia to a greater degree than that observed with PEG-IFN/ribavirin alone; eczematous rash, which can be severe in a minority of patients; and anorectal discomfort.

Ancillary